WellnessGLOWNCT07760896
The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness
A study testing WILD 5 Wellness Program in people with Wellness, run by Saundra Jain at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn whether a 30-day structured wellness program may support physical and emotional well-being in adults who are already taking a GLP-1 or dual GIP/GLP-1 medication for an FDA-approved indication. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Wellness
- What is being tested?
- WILD 5 Wellness Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Sep 2026to Oct 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Inclusion Criteria: Age 18 years or older. Able to speak, read, and understand English. Interested in supporting physical and emotional well-being. Access to a reliable Internet-enabled device, such as a computer, smartphone, or tablet.
Possess basic skills needed to complete online study forms. Currently prescribed and taking a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist by a licensed healthcare practitioner.
Report that the medication was prescribed for an FDA-approved indication, such as type 2 diabetes mellitus, chronic weight management for obesity or overweight with at least one weight-related condition, moderate-to-severe obstructive sleep apnea in adults with obesity, or another FDA-approved cardiometabolic indication.
Willing to complete online consent, registration, program measures, and daily tracking forms.
Willing to participate in the 30-day WILD 5 Wellness program delivered as part of the GLOW Study.
-
Exclusion Criteria: Under 18 years of age. Unable to speak, read, or understand English. Do not have access to a reliable Internet-enabled device. Do not possess basic skills needed to complete online study forms. Not currently prescribed and taking a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist by a licensed healthcare practitioner.
Report that the medication was not prescribed for an FDA-approved indication. Pregnant or planning to become pregnant in the next 30 days. Currently have thoughts about harming themselves or someone else. Currently experiencing symptoms suggestive of active psychosis. Unwilling or unable to complete the required online study forms or participate in the 30-day
-
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
The GLOW Study
The Colony, Texas, 75056
Saundra Jain, MA, PsyD, LPC, 888-252-7806, saundrajain@gmail.com
saundrajain@gmail.com
About this study
The goal of this clinical trial is to learn whether a 30-day structured wellness program may support physical and emotional well-being in adults who are already taking a GLP-1 or dual GIP/GLP-1 medication for an FDA-approved indication. The study does not evaluate the GLP-1 medication itself or make changes to participants' medication treatment.
The main questions it aims to answer are:
Read more
- Are there changes in participants' physical and emotional well-being after completing the 30-day wellness program?
- Are there changes in areas such as mood, anxiety, functioning, mindfulness, self-compassion, eating-related behaviors, pain, and positive wellness?
Participants will:
- Complete online questionnaires before and after the program.
- Follow the WILD 5 Wellness program for 30 days, which includes daily practices related to exercise, mindfulness, sleep, social connection, and nutrition.
- Complete a brief online tracking form each day during the 30-day program.
- Conditions
- Wellness
- Being tested
- WILD 5 Wellness Program
- Keywords
- GLP-1, GLP-1 Receptor Agonist, GIP/GLP-1 Receptor Agonist, Lifestyle Intervention, WILD 5 Wellness, Physical Well-Being, Emotional Well-Being, Self-Management
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WILD 5 Wellness ProgramBehavioural
A 30-day structured wellness program that includes daily practices in five areas: exercise, mindfulness, sleep, social connection, and nutrition. Participants complete the wellness practices independently and complete daily online tracking during the 30-day program.
| Study group | Role | What they receive |
|---|---|---|
| WILD 5 Wellness Program | Experimental | Participants will complete the 30-day WILD 5 Wellness program, which includes daily practices related to exercise, mindfulness, sleep, social connection, and nutrition. Receives: Behavioral: WILD 5 Wellness Program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in HERO Wellness Scale Total Score From Baseline to Post-Program
The HERO Wellness Scale is a 5-item self-report measure assessing happiness, enthusiasm, resilience, optimism, and perceived mental wellness. Total scores range from 0 to 50, with higher scores indicating greater mental wellness. The outcome will be the change in total score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Secondary outcomes (10)
Change in Patient Health Questionnaire-9 (PHQ-9) Total Score From Baseline to Post-Program
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure of depressive symptom severity. Total scores range from 0 to 27, with lower scores indicating fewer depressive symptoms. The outcome will be the change in total score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Change in Generalized Anxiety Disorder-7 (GAD-7) Total Score From Baseline to Post-Program
The Generalized Anxiety Disorder-7 (GAD-7) is a 7-item self-report measure of anxiety symptoms. Total scores range from 0 to 21, with lower scores indicating fewer anxiety symptoms. The outcome will be the change in total score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Change in Brief Pain Inventory Average Pain Score From Baseline to Post-Program
The Brief Pain Inventory Average Pain item is a self-report measure of pain severity. Scores range from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as the participant can imagine. The outcome will be the change in score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Change in Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score From Baseline to Post-Program
The Cognitive and Physical Functioning Questionnaire (CPFQ) is a 7-item self-report measure of cognitive and physical functioning. Total scores range from 7 to 42, with lower scores indicating better cognitive and physical functioning. The outcome will be the change in total score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Change in Eating and Appraisal Due to Emotions and Stress (EADES) Total Score From Baseline to Post-Program
The Eating and Appraisal Due to Emotions and Stress (EADES) scale is a self-report measure of emotion- and stress-related eating. Total scores range from 24 to 120, with lower scores indicating greater emotion- and stress-related eating. The outcome will be the change in total score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Change in Mindful Attention Awareness Scale (MAAS) Total Score From Baseline to Post-Program
The Mindful Attention Awareness Scale (MAAS) is a 15-item self-report measure of mindfulness and attention to present-moment experiences. Total scores range from 15 to 90, with higher scores indicating greater mindfulness. The outcome will be the change in total score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Change in Sleep Condition Indicator (SCI) Total Score From Baseline to Post-Program
The Sleep Condition Indicator (SCI) is an 8-item self-report measure of sleep problems. Total scores range from 0 to 32, with lower scores indicating greater sleep problems. The outcome will be the change in total score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Change in Social Connectedness Scale Total Score From Baseline to Post-Program
The Social Connectedness Scale is a self-report measure of perceived social connectedness. Total scores range from 8 to 48, with higher scores indicating greater social connectedness. The outcome will be the change in total score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Change in World Health Organization-5 Well-Being Index (WHO-5) Total Score From Baseline to Post-Program
The World Health Organization-5 Well-Being Index (WHO-5) is a 5-item self-report measure of subjective well-being. Total scores range from 0 to 25, with higher scores indicating greater well-being. The outcome will be the change in total score from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Change in Sheehan Disability Scale (SDS) Scores From Baseline to Post-Program
The Sheehan Disability Scale (SDS) is a self-report measure of functional impairment in work or school, social life, and family life. Each domain is rated from 0 to 10, with higher scores indicating greater functional impairment. The outcome will be the change in SDS scores from pre-program baseline to post-program assessment.
Measured: Baseline and end of 30-day intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2026
- Study start15 Sep 2026 (estimated)
- Primary completionOct 2027 (estimated)
- Study completionOct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for WellnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Saundra Jain
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Saundra Jain, University of Texas at Austin
- Investigators
- Saundra Jain, MA, PsyD, LPC, Principal investigator, The University of Texas at Austin School of NursingRakesh Jain, MD, MPH, Principal investigator, Texas Tech University Health Sciences Center School of Medicine - Permian Basin
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07760896
- Sponsor's protocol ID
- GLOW2026
- Acronym
- GLOW
- Status last verified
- Sep 2026
- First submitted
- 7 Aug 2026
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared outside the study team unless required by law or regulation or approved by the Institutional Review Board. Study findings may be presented or published only in aggregate or de-identified form.
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness
- ClinicalTrials.gov ID
- NCT07760896
- Acronym / sponsor ID
- GLOW / GLOW2026
- Conditions
- Wellness
- Keywords
- GLP-1, GLP-1 Receptor Agonist, GIP/GLP-1 Receptor Agonist, Lifestyle Intervention, WILD 5 Wellness, Physical Well-Being, Emotional Well-Being, Self-Management
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Saundra JainUniversity, hospital or other
- Study start
- 15 Sep 2026 (estimated)
- Primary completion
- Oct 2027 (estimated)
- Study completion
- Oct 2027 (estimated)
- First posted
- 12 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether a 30-day structured wellness program may support physical and emotional well-being in adults who are already taking a GLP-1 or dual GIP/GLP-1 medication for an FDA-approved indication. The study does not evaluate the GLP-1 medication itself or make changes to participants' medication treatment.
The main questions it aims to answer are:
- Are there changes in participants' physical and emotional well-being after completing the 30-day wellness program?
- Are there changes in areas such as mood, anxiety, functioning, mindfulness, self-compassion, eating-related behaviors, pain, and positive wellness?
Participants will:
- Complete online questionnaires before and after the program.
- Follow the WILD 5 Wellness program for 30 days, which includes daily practices related to exercise, mindfulness, sleep, social connection, and nutrition.
- Complete a brief online tracking form each day during the 30-day program.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| WILD 5 Wellness Program | Experimental | Behavioral: WILD 5 Wellness ProgramParticipants will complete the 30-day WILD 5 Wellness program, which includes daily practices related to exercise, mindfulness, sleep, social connection, and nutrition. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WILD 5 Wellness ProgramA 30-day structured wellness program that includes daily practices in five areas: exercise, mindfulness, sleep, social connection, and nutrition. Participants complete the wellness practices independently and complete daily online tracking during the 30-day program. | Behavioural | WILD 5 Wellness Program |
Primary outcome
Change in HERO Wellness Scale Total Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
The HERO Wellness Scale is a 5-item self-report measure assessing happiness, enthusiasm, resilience, optimism, and perceived mental wellness. Total scores range from 0 to 50, with higher scores indicating greater mental wellness. The outcome will be the change in total score from pre-program baseline to post-program assessment.
10 secondary outcomes
Change in Patient Health Questionnaire-9 (PHQ-9) Total Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Change in Generalized Anxiety Disorder-7 (GAD-7) Total Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Change in Brief Pain Inventory Average Pain Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Change in Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Change in Eating and Appraisal Due to Emotions and Stress (EADES) Total Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Change in Mindful Attention Awareness Scale (MAAS) Total Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Change in Sleep Condition Indicator (SCI) Total Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Change in Social Connectedness Scale Total Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Change in World Health Organization-5 Well-Being Index (WHO-5) Total Score From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Change in Sheehan Disability Scale (SDS) Scores From Baseline to Post-Program
Time frame: Baseline and end of 30-day intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- The GLOW Study websiteLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data will not be shared outside the study team unless required by law or regulation or approved by the Institutional Review Board. Study findings may be presented or published only in aggregate or de-identified form.
Related trials for Wellness
Not yet recruiting
GOT VOICE Feasibility With In-Person Group Singing
Elderly, Coronary Arterial Disease (CAD)
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Active, not recruiting
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
Human Papilloma Virus (HPV) Vaccine
Recruiting
Demographic Data Collection in Healthcare
Implementation Strategies
Not yet recruiting
ACUTE EFFECTS OF HIGH-INTENSITY LASER THERAPY ON PAIN, MUSCLE STIFFNESS, AND GRIP STRENGTH IN HEALTHY ADULTS
Exercise-Induced Muscle Fatigue, Fatigue Recovery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Saundra Jain, MA, PsyD, LPC principal investigator
The University of Texas at Austin School of Nursing
Rakesh Jain, MD, MPH principal investigator
Texas Tech University Health Sciences Center School of Medicine - Permian Basin
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WILD 5 Wellness Program in people with Wellness, run by Saundra Jain at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Saundra Jain, MA, PsyD, LPC (888-252-7806, saundrajain@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in HERO Wellness Scale Total Score From Baseline to Post-Program (time frame: Baseline and end of 30-day intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.